Brompheniramine
A first-generation antihistamine used to relieve symptoms of allergic rhinitis, hay fever, and the common cold, including sneezing, runny nose, and itching. It blocks histamine H1 receptors and has mild sedative and anticholinergic properties. It is commonly found in combination cold and allergy products.
Molecular Weight
319.2400 g/mol
LogP
3.50
TPSA
16.10 Ų
Lipinski RO5
Pass
Mechanism of Action
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
2D Structure
Cite this structure
Embed this structure
SMILES
CN(C)CCC(c1ccc(Br)cc1)c1ccccn1
InChI
InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
Molecular Formula
C16H19BrN2
HBD / HBA
- / 2
Rotatable Bonds
5
Heavy Atoms
19
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
A first-generation antihistamine used to relieve symptoms of allergic rhinitis, hay fever, and the common cold, including sneezing, runny nose, and itching. It blocks histamine H1 receptors and has mild sedative and anticholinergic properties. It is commonly found in combination cold and allergy products.
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Yes, Brompheniramine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL811. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6834. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="brompheniramine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/brompheniramine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/brompheniramine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/brompheniramine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="brompheniramine"></drugfyi-drug>